Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT4PXBTA)

DOT Name Tumor necrosis factor ligand superfamily member 10 (TNFSF10)
Synonyms Apo-2 ligand; Apo-2L; TNF-related apoptosis-inducing ligand; Protein TRAIL; CD antigen CD253
Gene Name TNFSF10
UniProt ID
TNF10_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1D0G; 1D2Q; 1D4V; 1DG6; 1DU3; 4N90; 5CIR
Pfam ID
PF00229
Sequence
MAMMEVQGGPSLGQTCVLIVIFTVLLQSLCVAVTYVYFTNELKQMQDKYSKSGIACFLKE
DDSYWDPNDEESMNSPCWQVKWQLRQLVRKMILRTSEETISTVQEKQQNISPLVRERGPQ
RVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKG
FYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLY
SIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG
Function
Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.
Tissue Specificity Widespread; most predominant in spleen, lung and prostate.
KEGG Pathway
Cytokine-cytokine receptor interaction (hsa04060 )
Viral protein interaction with cytokine and cytokine receptor (hsa04061 )
FoxO sig.ling pathway (hsa04068 )
Apoptosis (hsa04210 )
Necroptosis (hsa04217 )
.tural killer cell mediated cytotoxicity (hsa04650 )
Pathogenic Escherichia coli infection (hsa05130 )
Salmonella infection (hsa05132 )
Influenza A (hsa05164 )
Lipid and atherosclerosis (hsa05417 )
Reactome Pathway
Regulation by c-FLIP (R-HSA-3371378 )
RIPK1-mediated regulated necrosis (R-HSA-5213460 )
CASP8 activity is inhibited (R-HSA-5218900 )
Dimerization of procaspase-8 (R-HSA-69416 )
TRAIL signaling (R-HSA-75158 )
Caspase activation via Death Receptors in the presence of ligand (R-HSA-140534 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 5 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
DTI-015 DMXZRW0 Approved Tumor necrosis factor ligand superfamily member 10 (TNFSF10) affects the response to substance of DTI-015. [75]
Simvastatin DM30SGU Approved Tumor necrosis factor ligand superfamily member 10 (TNFSF10) increases the response to substance of Simvastatin. [76]
Atorvastatin DMF28YC Phase 3 Trial Tumor necrosis factor ligand superfamily member 10 (TNFSF10) increases the response to substance of Atorvastatin. [76]
SC-236 DMO1URE Terminated Tumor necrosis factor ligand superfamily member 10 (TNFSF10) affects the response to substance of SC-236. [77]
Apigenin DMI3491 Investigative Tumor necrosis factor ligand superfamily member 10 (TNFSF10) increases the response to substance of Apigenin. [78]
------------------------------------------------------------------------------------
This DOT Affected the Regulation of Drug Effects of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
5-Fluoro-2'-Deoxyuridine-5'-Monophosphate DME1AGO Investigative Tumor necrosis factor ligand superfamily member 10 (TNFSF10) increases the abundance of 5-Fluoro-2'-Deoxyuridine-5'-Monophosphate. [79]
------------------------------------------------------------------------------------
64 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [1]
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [2]
Tretinoin DM49DUI Approved Tretinoin increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [3]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [4]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [5]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [6]
Cisplatin DMRHGI9 Approved Cisplatin increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [7]
Estradiol DMUNTE3 Approved Estradiol decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [2]
Quercetin DM3NC4M Approved Quercetin decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [9]
Temozolomide DMKECZD Approved Temozolomide increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [10]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [11]
Vorinostat DMWMPD4 Approved Vorinostat increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [12]
Triclosan DMZUR4N Approved Triclosan affects the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [13]
Methotrexate DM2TEOL Approved Methotrexate increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [14]
Decitabine DMQL8XJ Approved Decitabine increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [15]
Selenium DM25CGV Approved Selenium decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [16]
Phenobarbital DMXZOCG Approved Phenobarbital affects the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [17]
Progesterone DMUY35B Approved Progesterone decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [18]
Fluorouracil DMUM7HZ Approved Fluorouracil increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [19]
Demecolcine DMCZQGK Approved Demecolcine increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [20]
Isotretinoin DM4QTBN Approved Isotretinoin increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [21]
Bortezomib DMNO38U Approved Bortezomib decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [22]
Troglitazone DM3VFPD Approved Troglitazone decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [23]
Cytarabine DMZD5QR Approved Cytarabine increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [24]
Irinotecan DMP6SC2 Approved Irinotecan increases the activity of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [26]
Testosterone enanthate DMB6871 Approved Testosterone enanthate affects the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [27]
Paclitaxel DMLB81S Approved Paclitaxel increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [28]
Sodium lauryl sulfate DMLJ634 Approved Sodium lauryl sulfate decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [29]
Menthol DMG2KW7 Approved Menthol decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [30]
Capsaicin DMGMF6V Approved Capsaicin increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [33]
Alitretinoin DMME8LH Approved Alitretinoin increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [34]
Thalidomide DM70BU5 Approved Thalidomide decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [35]
Diphenylpyraline DMW4X37 Approved Diphenylpyraline increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [38]
Beta-carotene DM0RXBT Approved Beta-carotene increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [39]
Cholecalciferol DMGU74E Approved Cholecalciferol affects the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [40]
Ximelegatran DMU8ANS Approved Ximelegatran decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [43]
Dihydroxyacetone DMM1LG2 Approved Dihydroxyacetone decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [44]
Tofacitinib DMBS370 Approved Tofacitinib decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [45]
Cantharidin DMBP5N3 Approved Cantharidin increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [46]
Sanguinarine DMDINFS Approved Sanguinarine increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [47]
Urethane DM7NSI0 Phase 4 Urethane decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [49]
Resveratrol DM3RWXL Phase 3 Resveratrol increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [50]
Tamibarotene DM3G74J Phase 3 Tamibarotene increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [51]
Epigallocatechin gallate DMCGWBJ Phase 3 Epigallocatechin gallate decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [52]
Curcumin DMQPH29 Phase 3 Curcumin decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [53]
Tocopherol DMBIJZ6 Phase 2 Tocopherol decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [16]
Flavopiridol DMKSUOI Phase 2 Flavopiridol increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [55]
(+)-JQ1 DM1CZSJ Phase 1 (+)-JQ1 decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [57]
Leflunomide DMR8ONJ Phase 1 Trial Leflunomide decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [58]
LY294002 DMY1AFS Phase 1 LY294002 increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [50]
PMID27336223-Compound-5 DM6E50A Patented PMID27336223-Compound-5 increases the activity of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [60]
PMID28870136-Compound-49 DMTUC9E Patented PMID28870136-Compound-49 increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [61]
Celastrol DMWQIJX Preclinical Celastrol increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [62]
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [63]
Formaldehyde DM7Q6M0 Investigative Formaldehyde increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [20]
Milchsaure DM462BT Investigative Milchsaure decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [64]
Sulforaphane DMQY3L0 Investigative Sulforaphane increases the activity of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [65]
Glyphosate DM0AFY7 Investigative Glyphosate decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [66]
Nickel chloride DMI12Y8 Investigative Nickel chloride decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [67]
D-glucose DMMG2TO Investigative D-glucose decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [68]
Phencyclidine DMQBEYX Investigative Phencyclidine increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [69]
OXYQUINOLINE DMZVS9Y Investigative OXYQUINOLINE increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [9]
Dimethylformamide DML6O4N Investigative Dimethylformamide increases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [72]
4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol DMTMLXU Investigative 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol decreases the expression of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [73]
------------------------------------------------------------------------------------
⏷ Show the Full List of 64 Drug(s)
2 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Arsenic DMTL2Y1 Approved Arsenic increases the methylation of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [8]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the methylation of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [56]
------------------------------------------------------------------------------------
16 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT
Drug Name Drug ID Highest Status Interaction REF
Aspirin DM672AH Approved Aspirin increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [25]
Azacitidine DMTA5OE Approved Azacitidine increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [31]
Sulindac DM2QHZU Approved Sulindac increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [32]
Vitamin C DMXJ7O8 Approved Vitamin C decreases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [36]
Sorafenib DMS8IFC Approved Sorafenib increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [37]
Lovastatin DM9OZWQ Approved Lovastatin increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [41]
Orlistat DMRJSP8 Approved Orlistat increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [42]
Bepridil DM0RKS4 Approved Bepridil increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [48]
Cibenzoline DMBG0N4 Phase 4 Cibenzoline increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [48]
Genistein DM0JETC Phase 2/3 Genistein increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [54]
Amiodarone DMUTEX3 Phase 2/3 Trial Amiodarone increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [48]
Ribavirin DMEYLH9 Phase 1 Trial Ribavirin decreases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [59]
SB 203580 DMAET6F Terminated SB 203580 increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [54]
Chrysin DM7V2LG Investigative Chrysin increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [70]
gingerol DMNXYSM Investigative gingerol increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [71]
EM-101 DMQ63J2 Investigative EM-101 increases the response to substance of Tumor necrosis factor ligand superfamily member 10 (TNFSF10). [74]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)

References

1 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
2 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
3 Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
4 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
5 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
6 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
7 Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
8 Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
9 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
10 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
11 Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
12 Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther. 2007 Nov;6(11):2967-75. doi: 10.1158/1535-7163.MCT-04-0344.
13 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
14 Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
15 Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 2007 Feb 1;67(3):1203-11. doi: 10.1158/0008-5472.CAN-06-2310.
16 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
17 Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
18 Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
19 TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther. 2008 Dec;7(12):2034-8. doi: 10.4161/cbt.7.12.7460.
20 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
21 Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
22 Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther. 2006 Dec;5(12):3032-41. doi: 10.1158/1535-7163.MCT-05-0474.
23 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
24 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
25 Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res. 2008 May 15;14(10):3168-76. doi: 10.1158/1078-0432.CCR-07-4362.
26 Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005 Dec;4(12):2026-36. doi: 10.1158/1535-7163.MCT-05-0262.
27 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
28 Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
29 CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
30 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
31 Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther. 2009 Jan;328(1):107-15. doi: 10.1124/jpet.108.143560. Epub 2008 Sep 30.
32 TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol. 2011 Feb;223(3):378-89. doi: 10.1002/path.2797. Epub 2010 Oct 29.
33 Capsaicin sensitizes TRAIL-induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of Ca(2+) influx. Toxicol Appl Pharmacol. 2012 Feb 15;259(1):87-95. doi: 10.1016/j.taap.2011.12.010. Epub 2011 Dec 19.
34 Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM. Oncogene. 2006 Jun 22;25(26):3735-44. doi: 10.1038/sj.onc.1209410. Epub 2006 Jan 30.
35 Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. Haematologica. 2006 Mar;91(3):386-9.
36 Quercetin-3-O-(2"-galloyl)--l-rhamnopyranoside prevents TRAIL-induced apoptosis in human keratinocytes by suppressing the caspase-8- and Bid-pathways and the mitochondrial pathway. Chem Biol Interact. 2013 Aug 25;204(3):144-52. doi: 10.1016/j.cbi.2013.05.009. Epub 2013 May 24.
37 The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
38 Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
39 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
40 Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
41 Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol. 2008 Feb;86(3):273-83. doi: 10.1007/s11060-007-9475-3. Epub 2007 Oct 11.
42 Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem. 2008 Nov 14;283(46):31378-84. doi: 10.1074/jbc.M803384200. Epub 2008 Sep 16.
43 Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol. 2010 Nov;37(5):1297-305. doi: 10.3892/ijo_00000781.
44 The sunless tanning agent dihydroxyacetone induces stress response gene expression and signaling in cultured human keratinocytes and reconstructed epidermis. Redox Biol. 2020 Sep;36:101594. doi: 10.1016/j.redox.2020.101594. Epub 2020 May 29.
45 White-to-brown metabolic conversion of human adipocytes by JAK inhibition. Nat Cell Biol. 2015 Jan;17(1):57-67. doi: 10.1038/ncb3075. Epub 2014 Dec 8.
46 Anticancer effects of cantharidin in A431 human skin cancer (Epidermoid carcinoma) cells in vitro and in vivo. Environ Toxicol. 2017 Mar;32(3):723-738. doi: 10.1002/tox.22273. Epub 2016 Apr 25.
47 Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
48 Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
49 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
50 Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One. 2010 Dec 14;5(12):e15288. doi: 10.1371/journal.pone.0015288.
51 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
52 Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat Res. 2005 Dec 11;591(1-2):198-211.
53 Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther. 2005 Feb;4(2):233-41.
54 Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact. 2009 Jul 15;180(2):143-50. doi: 10.1016/j.cbi.2009.03.020. Epub 2009 Apr 5.
55 The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med. 2006 Aug;18(2):249-56.
56 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
57 Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
58 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
59 Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003 May 16;278(20):18092-100. doi: 10.1074/jbc.M300265200. Epub 2003 Mar 13.
60 Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
61 Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression. Biochem Pharmacol. 2009 Jan 1;77(1):30-45. doi: 10.1016/j.bcp.2008.09.018. Epub 2008 Sep 21.
62 The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells. J Biol Chem. 2015 Jan 16;290(3):1623-38.
63 Low dose of bisphenol a modulates ovarian cancer gene expression profile and promotes epithelial to mesenchymal transition via canonical Wnt pathway. Toxicol Sci. 2018 Aug 1;164(2):527-538.
64 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
65 TRAIL attenuates sulforaphane-mediated Nrf2 and sustains ROS generation, leading to apoptosis of TRAIL-resistant human bladder cancer cells. Toxicol Appl Pharmacol. 2018 Aug 1;352:132-141. doi: 10.1016/j.taap.2018.05.022. Epub 2018 May 22.
66 Glyphosate-based herbicides at low doses affect canonical pathways in estrogen positive and negative breast cancer cell lines. PLoS One. 2019 Jul 11;14(7):e0219610. doi: 10.1371/journal.pone.0219610. eCollection 2019.
67 Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
68 Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
69 Microarray Analysis of Gene Expression Alteration in Human Middle Ear Epithelial Cells Induced by Asian Sand Dust. Clin Exp Otorhinolaryngol. 2015 Dec;8(4):345-53. doi: 10.3342/ceo.2015.8.4.345. Epub 2015 Nov 10.
70 Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines. Toxicol In Vitro. 2011 Apr;25(3):630-5. doi: 10.1016/j.tiv.2010.12.013. Epub 2010 Dec 30.
71 Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells. Toxicol Appl Pharmacol. 2014 Sep 15;279(3):253-265. doi: 10.1016/j.taap.2014.06.030. Epub 2014 Jul 14.
72 TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J Leukoc Biol. 2008 Mar;83(3):621-9.
73 Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol. 2013 May;169(1):167-78.
74 Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27. Cell Death Dis. 2013 Oct 31;4(10):e890. doi: 10.1038/cddis.2013.413.
75 Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol. 2006 Jan 10;24(2):274-87. doi: 10.1200/JCO.2005.02.9405. Epub 2005 Dec 19.
76 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
77 Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene. 2002 Sep 5;21(39):6032-40. doi: 10.1038/sj.onc.1205897.
78 Apigenin promotes TRAIL-mediated apoptosis regardless of ROS generation. Food Chem Toxicol. 2018 Jan;111:623-630. doi: 10.1016/j.fct.2017.12.018. Epub 2017 Dec 13.
79 Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer. 2002 Jan;38(1):167-76. doi: 10.1016/s0959-8049(01)00339-2.